
Invitae Corporation NVTA
Quarterly report 2023-Q3
added 11-08-2023
Invitae Corporation Accounts Receivables 2011-2026 | NVTA
Accounts receivable — is the amount of money owed to a company by other organizations, individuals, or the government. It arises when a company has already delivered goods, performed work, or provided services, but has not yet received payment for them.Examples of accounts receivable
- Customers have not paid invoices for delivered products
- An advance has been paid to a supplier, but goods have not yet been received
- Employees have not reported on accountable amounts
- The government must refund tax overpayments
- Outstanding loans issued
- Asset quality
Accounts receivable are part of current assets. But they are not cash — they are promises. Investors assess how realistic these promises are to be collected. The higher the share of overdue or doubtful receivables, the greater the risk of asset impairment. - Impact on cash flow
Even if a company shows a profit, the money can be "tied up" in receivables. This means profit does not turn into actual cash, and the company may face liquidity shortages. - Assessment of management efficiency
The following accounts receivable turnover ratios are commonly used:
Receivables turnover = Revenue / Average accounts receivable
(the higher — the better)
Days Sales Outstanding (DSO) = 365 / Turnover
(the fewer days — the faster customers pay)
If the DSO is constantly increasing — this is a red flag — customers are delaying payments, and money gets stuck in settlements.
Annual Accounts Receivables Invitae Corporation
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 96.1 M | 66.2 M | 47.7 M | 32.5 M | 26.3 M | 10.4 M | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 96.1 M | 10.4 M | 46.6 M |
Quarterly Accounts Receivables Invitae Corporation
| 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 82.5 M | 85.6 M | 85.6 M | 96.1 M | 89.1 M | 82.6 M | 80.4 M | 66.2 M | 58.4 M | 55.7 M | 45.6 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 32.5 M | 32.5 M | 32.5 M | 32.5 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | 10.4 M | 10.4 M | 10.4 M | 10.4 M | 1.15 M | 1.15 M | 1.15 M | 1.15 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 96.1 M | 1.15 M | 42 M |
Accounts Receivables of other stocks in the Diagnostics research industry
| Issuer | Accounts Receivables | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
114 M | - | -17.87 % | $ 25.9 M | ||
|
BioNano Genomics
BNGO
|
4.75 M | $ 1.12 | -0.88 % | $ 1.42 M | ||
|
Burning Rock Biotech Limited
BNR
|
88.2 M | $ 28.4 | -1.41 % | $ 306 M | ||
|
Aspira Women's Health
AWH
|
1.24 M | - | -6.19 % | $ 10.5 M | ||
|
Accelerate Diagnostics
AXDX
|
2.42 M | - | -61.36 % | $ 2.46 M | ||
|
Biocept
BIOC
|
2.15 M | - | -13.05 % | $ 7.29 M | ||
|
Chembio Diagnostics
CEMI
|
6.54 M | - | 0.22 % | $ 16.8 M | ||
|
DarioHealth Corp.
DRIO
|
3.16 M | $ 11.26 | - | $ 319 M | ||
|
Enzo Biochem
ENZ
|
3.99 M | - | -8.98 % | $ 14.8 K | ||
|
Co-Diagnostics
CODX
|
304 K | - | - | $ 79.8 M | ||
|
Global Cord Blood Corporation
CO
|
416 M | - | - | $ 399 M | ||
|
Fulgent Genetics
FLGT
|
69 M | $ 23.02 | 0.04 % | $ 696 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.3 B | $ 209.34 | 0.95 % | $ 23.2 B | ||
|
Castle Biosciences
CSTL
|
51.2 M | $ 30.02 | 3.73 % | $ 834 M | ||
|
CareDx, Inc
CDNA
|
51.1 M | $ 19.18 | 2.08 % | $ 1.03 B | ||
|
Danaher Corporation
DHR
|
3.91 B | $ 209.79 | -0.58 % | $ 153 B | ||
|
DermTech
DMTK
|
2.58 M | - | -11.32 % | $ 2.94 M | ||
|
DexCom
DXCM
|
1.22 B | $ 72.99 | -0.38 % | $ 28.5 B | ||
|
Interpace Biosciences
IDXG
|
8.54 M | $ 1.74 | -5.95 % | $ 7.63 M | ||
|
Exact Sciences Corporation
EXAS
|
299 M | $ 103.46 | 0.07 % | $ 19.5 B | ||
|
Guardant Health
GH
|
138 M | $ 96.45 | 2.15 % | $ 12.1 B | ||
|
QIAGEN N.V.
QGEN
|
381 M | - | - | $ 10.6 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.1 B | $ 287.1 | 0.62 % | $ 24.1 B | ||
|
Charles River Laboratories International
CRL
|
709 M | $ 166.77 | 1.98 % | $ 8.27 B | ||
|
Heska Corporation
HSKA
|
29.5 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
1.42 M | - | -20.0 % | $ 1.06 M | ||
|
ICON Public Limited Company
ICLR
|
1.34 B | $ 104.81 | 0.14 % | $ 8.65 B | ||
|
ENDRA Life Sciences
NDRA
|
6.85 K | $ 3.77 | 0.53 % | $ 2.02 M | ||
|
IDEXX Laboratories
IDXX
|
552 M | $ 648.66 | 4.1 % | $ 52.2 B | ||
|
Illumina
ILMN
|
735 M | $ 123.46 | 2.42 % | $ 19.6 B | ||
|
IQVIA Holdings
IQV
|
3.4 B | $ 164.94 | 1.75 % | $ 28.4 B | ||
|
Motus GI Holdings
MOTS
|
76 K | - | -34.28 % | $ 263 K | ||
|
Mettler-Toledo International
MTD
|
778 M | $ 1 382.99 | -0.81 % | $ 28.5 B | ||
|
Biodesix
BDSX
|
8.6 M | $ 13.28 | 3.99 % | $ 1.72 B | ||
|
Natera
NTRA
|
244 M | $ 209.72 | 0.18 % | $ 20.6 B | ||
|
Lantheus Holdings
LNTH
|
321 M | $ 73.43 | 0.01 % | $ 5.08 B | ||
|
Biomerica
BMRA
|
731 K | $ 2.11 | 0.49 % | $ 4.85 M | ||
|
Bioventus
BVS
|
123 M | $ 8.71 | 0.58 % | $ 546 M | ||
|
Medpace Holdings
MEDP
|
402 M | $ 442.92 | -0.46 % | $ 12.8 B |